Ocugen (OCGN) Q2 Revenue Jumps 20%

Ocugen (NASDAQ:OCGN), a biotechnology company developing gene therapies and regenerative medicine solutions for eye diseases, released its results for the second quarter of fiscal 2025 on August 1, 2025. GAAP revenue was $1.373 million, well above the $0.47 million analyst estimate (GAAP), as it secured new licensing agreements and continued R&D collaborations. The net loss per share (GAAP) narrowed to $(0.05), compared to consensus expectations of $(0.06) (GAAP) and last year's GAAP net loss per share was $(0.06). The quarter showed progress on clinical trials and strategic deals, but cash levels continued to fall as spending outpaced inflows. Overall, the period featured accelerated clinical milestones and partnership activity, but ongoing losses and cash burn signal future funding will be needed to sustain development. Source: Analyst estimates for the quarter provided by FactSet. Ocugen is focused on developing treatments for vision-threatening diseases. Its main focus is gene therapy, a technique that uses genetic material to treat or prevent disease. The company's lead gene therapy candidates target inherited retinal diseases like retinitis pigmentosa and Stargardt disease, as well as age-related macular degeneration.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool